Neurocrine Biosciences Inc (NBIX)
Debt-to-assets ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | 0 | 335,100 | 317,900 |
| Total assets | US$ in thousands | 3,718,700 | 3,251,400 | 2,368,700 | 2,072,500 | 1,734,700 |
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.16 | 0.18 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $3,718,700K
= 0.00
Based on the provided data, Neurocrine Biosciences Inc's debt-to-assets ratio has shown a decreasing trend over the years. As of December 31, 2020, the ratio was 0.18, indicating that 18% of the company's assets were financed by debt. However, by December 31, 2021, the ratio had improved to 0.16, showing a decrease in the proportion of debt relative to the assets.
Interestingly, starting from December 31, 2022, the debt-to-assets ratio dropped to 0.00 and remained at this level till December 31, 2024. A debt-to-assets ratio of 0.00 signifies that the company had no debt financing its assets during these years, which could indicate a strong financial position with lower financial risk and potentially better solvency.
Overall, the decreasing trend in the debt-to-assets ratio, leading to a zero ratio in the later years, suggests that Neurocrine Biosciences Inc has been effectively managing its debt levels and maintaining a healthy balance between debt and assets in its capital structure.
Peer comparison
Dec 31, 2024